Pharsight

Drugs that contain Donepezil Hydrochloride; Memantine Hydrochloride

1. Namzaric patents expiration

NAMZARIC's oppositions filed in EPO
NAMZARIC IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5061703 ABBVIE Adamantane derivatives in the prevention and treatment of cerebral ischemia
Apr, 2015

(9 years ago)

US5061703

(Pediatric)

ABBVIE Adamantane derivatives in the prevention and treatment of cerebral ischemia
Oct, 2015

(8 years ago)

US8173708 ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 5 months from now)

US8168209 ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 5 months from now)

US8329752 ABBVIE Composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 5 months from now)

US8598233 ABBVIE Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 5 months from now)

US8283379 ABBVIE Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 5 months from now)

US8362085 ABBVIE Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(1 year, 5 months from now)

US8338486 ABBVIE Methods for the treatment of CNS-related conditions
Nov, 2025

(1 year, 5 months from now)

US8580858 ABBVIE Compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 5 months from now)

US8293794 ABBVIE Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 5 months from now)

US8338485 ABBVIE Compositions for the treatment of CNS-related conditions
Nov, 2025

(1 year, 5 months from now)

US8283379

(Pediatric)

ABBVIE Methods and compositions for the treatment of CNS-related conditions
May, 2026

(1 year, 11 months from now)

US8168209

(Pediatric)

ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(1 year, 11 months from now)

US8329752

(Pediatric)

ABBVIE Composition for administering an NMDA receptor antagonist to a subject
May, 2026

(1 year, 11 months from now)

US8598233

(Pediatric)

ABBVIE Method for administering an NMDA receptor antagonist to a subject
May, 2026

(1 year, 11 months from now)

US8362085

(Pediatric)

ABBVIE Method for administering an NMDA receptor antagonist to a subject
May, 2026

(1 year, 11 months from now)

US8173708

(Pediatric)

ABBVIE Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(1 year, 11 months from now)

US8039009 ABBVIE Modified release formulations of memantine oral dosage forms
Mar, 2029

(4 years from now)

US8039009

(Pediatric)

ABBVIE Modified release formulations of memantine oral dosage forms
Sep, 2029

(5 years from now)

US8058291 ABBVIE Methods and compositions for the treatment of CNS-related conditions
Dec, 2029

(5 years from now)

Market Authorisation Date: 18 July, 2016

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of NAMZARIC before it's drug patent expiration?
More Information on Dosage

NAMZARIC family patents

Family Patents